Brief: Selecta Biosciences And Astellas Pharma Inc Announce Exclusive Licensing And Development Agreement For Xork Igg Protease

Cartesian Therapeutics

09/01/2023 12:44

Jan 9 (Reuters) - Astellas Pharma Inc  4503.T :
    * SELECTA BIOSCIENCES AND ASTELLAS ANNOUNCE EXCLUSIVE
LICENSING
AND DEVELOPMENT AGREEMENT FOR XORK IGG PROTEASE
    * SELECTA BIOSCIENCES - TO GET $10M UPFRONT PAYMENT &
ELIGIBLE TO
GET UP TO $340M FOR CERTAIN ADDITIONAL MILESTONES PLUS ROYALTIES
ON COMMERCIAL SALES
    * SELECTA BIOSCIENCES INC - SELECTA IS RESPONSIBLE FOR
DEVELOPMENT
AND MANUFACTURING OF XORK
    * SELECTA BIOSCIENCES INC - WILL MAINTAIN RIGHTS FOR
DEVELOPMENT
OF ADDITIONAL INDICATIONS BEYOND POMPE DISEASE
    * SELECTA - ASTELLAS WOULD HAVE  EXCLUSIVE RIGHT TO
COMMERCIALIZE
XORK FOR USE IN POMPE DISEASE WITH ASTELLAS GENE THERAPY
INVESTIGATIONAL/AUTHORIZED PRODUCT

Source text for Eikon:  ID:nPn3YWv3La 
Further company coverage:  4503.T 
 ((reuters.briefs@thomsonreuters.com;))